- Home
- EVG vs CHRS Comparison
EVG vs CHRS Comparison
Compare EVG & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVG
- CHRS
- Stock Information
- Founded
- EVG 2005
- CHRS 2010
- Country
- EVG United States
- CHRS United States
- Employees
- EVG N/A
- CHRS N/A
- Industry
- EVG Investment Managers
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVG Finance
- CHRS Health Care
- Exchange
- EVG Nasdaq
- CHRS Nasdaq
- Market Cap
- EVG 149.9M
- CHRS 134.4M
- IPO Year
- EVG N/A
- CHRS 2014
- Fundamental
- Price
- EVG $11.19
- CHRS $1.07
- Analyst Decision
- EVG
- CHRS Strong Buy
- Analyst Count
- EVG 0
- CHRS 4
- Target Price
- EVG N/A
- CHRS $5.38
- AVG Volume (30 Days)
- EVG 49.4K
- CHRS 2.0M
- Earning Date
- EVG 01-01-0001
- CHRS 03-12-2025
- Dividend Yield
- EVG 8.68%
- CHRS N/A
- EPS Growth
- EVG N/A
- CHRS N/A
- EPS
- EVG N/A
- CHRS N/A
- Revenue
- EVG N/A
- CHRS $304,340,000.00
- Revenue This Year
- EVG N/A
- CHRS $2.07
- Revenue Next Year
- EVG N/A
- CHRS N/A
- P/E Ratio
- EVG N/A
- CHRS N/A
- Revenue Growth
- EVG N/A
- CHRS 44.19
- 52 Week Low
- EVG $9.13
- CHRS $0.66
- 52 Week High
- EVG $10.86
- CHRS $2.65
- Technical
- Relative Strength Index (RSI)
- EVG 54.97
- CHRS 39.03
- Support Level
- EVG $11.14
- CHRS $1.06
- Resistance Level
- EVG $11.27
- CHRS $1.16
- Average True Range (ATR)
- EVG 0.10
- CHRS 0.08
- MACD
- EVG -0.01
- CHRS 0.00
- Stochastic Oscillator
- EVG 55.56
- CHRS 5.56
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.